Answer
It is unknown whether caplacizumab passes into human breast milk, and a risk to the child cannot be excluded; whether to stop breastfeeding or abstain from or discontinue treatment must be decided by weighing breastfeeding benefits for the child against treatment benefits for the woman.
Sources for this answer
- Cablivi 10 mg powder and solvent for solution for injectionSANOFI · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 10Document updated
Sources checked